IRVINE, Calif. and LIEGE, Belgium, Nov. 7, 2013 (GLOBE NEWSWIRE) -- MDxHealth SA (NYSE Euronext:MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, today announced that CEO, Dr. Jan Groen, will present at the Canaccord Genuity Medical Technology & Diagnostics Forum in New York on November 14 at 3:30 pm. The presentation will be posted under the investor tab of the MDxHealth website ( http://mdxhealth.com/investors/shareholder-information ).
About MDxHealth ®
MDxHealth is a molecular diagnostics company that develops and commercializes advanced epigenetic tests for cancer assessment and the personalized treatment of patients. The company's first commercial product, ConfirmMDx TM for Prostate Cancer, has been shown to help distinguish patients who have a true-negative biopsy from those who may have undetected cancer. MDxHealth helps to address a large and growing unmet medical need for better cancer diagnosis and treatment information. The company has a proprietary platform and a strong epigenetic product pipeline focused on the development of products for prostate, brain and lung cancers. The company is based in Irvine, California with a European headquarters in Herstal, Belgium. For more information visit MDxHealth's website at www.mdxhealth.com .
For more information:
| Dr. Jan Groen, CEO | Mike Sinclair (Media) | Matt Clawson |
| MDxHealth | Halsin Partners | Allen & Caron, Inc |
| US: +1 949 812 6979 | UK: +44 20 7318 2955 | US: +1 949 474 4300 |
| BE: +32 4 364 20 70 | Cell:+44 7968 022075 | |
| info@mdxhealth.com | msinclair@halsin.com | matt@allencaron.com |
This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.
NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.
To access the PDF version, please click here: http://hugin.info/137314/R/1741084/584831.pdf
